Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batoclimab in Active Thyroid Eye Disease (TED)
NCT05524571Phase 3Completed
- Sponsor
- Immunovant, Inc.
- Start
- Jan 2023
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of batoclimab in thyroid eye disease (TED), sponsored by Immunovant, Inc.. Started Jan 2023; status: completed.
02
Drugs
batoclimab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT05524571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524571.